Description
KIT BD SARS-COV-2
First action · last action
2021-12-20 · 2022-11-25
Transactions
2
First transaction's obligation
$199,930
Base + all options value (sum of deltas)
$284,604
Extent competed
NOT COMPETED UNDER SAP
Other than full & open authority
SAP NON-COMPETITION (FAR 13)
Set-aside
NO SET ASIDE USED.
Offers received
1
SDVOSB flag on record
No
NAICS
325413 · IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING
Modification chain · 2 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2021-12-20+$199,930= $199,930
- Mod P000012022-11-25+$84,675= $284,604
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2021-12-20 | +$199,930 | $199,930 | KIT BD SARS-COV-2 |
| Mod P00001· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2022-11-25 | +$84,675 | $284,604 | KIT BD SARS-COV-2 |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI DP4CNEMUF5F3)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C25926N0457 | NETWORK CONTRACT OFFICE 19 (36C259) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $147,256 | FY2026 |
| 36C25926N0454 | NETWORK CONTRACT OFFICE 19 (36C259) · 6640 · LABORATORY EQUIPMENT AND SUPPLIES | $114,883 | FY2026 |
| 36C25726N0477 | 257-NETWORK CONTRACT OFFICE 17 (36C257) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $337,374 | FY2026 |
| 36C25726D0094 | 257-NETWORK CONTRACT OFFICE 17 (36C257) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $0 | FY2026 |
| 36C24526P0552 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $98,508 | FY2026 |
| 36C24126N0587 | 241-NETWORK CONTRACT OFFICE 01 (36C241) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $2,457 | FY2026 |
Other recipients under 6550 from 242-NETWORK CONTRACT OFFICE 02 (36C242) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36C24226N0602 | ORTHO-CLINICAL DIAGNOSTICS, INC | 242-NETWORK CONTRACT OFFICE 02 (36C242) | $326,624 | FY2026 |
| 36C24226N0475 | BIOMERIEUX INC | 242-NETWORK CONTRACT OFFICE 02 (36C242) | $251,376 | FY2026 |
| 36C24226N0479 | BIOMERIEUX INC | 242-NETWORK CONTRACT OFFICE 02 (36C242) | $299,794 | FY2026 |
| 36C24226N0476 | BIOMERIEUX INC | 242-NETWORK CONTRACT OFFICE 02 (36C242) | $277,267 | FY2026 |
| 36C24226N0477 | BIOMERIEUX INC | 242-NETWORK CONTRACT OFFICE 02 (36C242) | $65,679 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_36C24222P0312_3600_-NONE-_-NONE- · retrieved 2026-09-26.